The immune-suppressing drug rapamycin, originally used for kidney transplants, is gaining attention for its potential to slow aging.

  • Rumbelows@lemmy.world
    link
    fedilink
    English
    arrow-up
    25
    ·
    1 month ago

    Fear not, this will only be available to the super rich.

    However, you will be able to feed your children by selling your organs, so we’ve got that going for us.

    • 200ok@lemmy.world
      link
      fedilink
      English
      arrow-up
      2
      ·
      1 month ago

      And then you’ll get a legit prescription for the drug!

      Step 3: profit!!!

    • Soulcreator@lemmy.world
      link
      fedilink
      English
      arrow-up
      14
      ·
      1 month ago

      See that’s the interesting thing about rapamycin, it’s an old drug that has been used for immuno-suppression for years now, only just now scientists are discovering this interesting side effect. The patient on rapamycin has expired so you can get a generic prescription for cheap.

      But ironically because the patent expired there’s no money in it for the drug companies to get it approved for longevity purposes, so who knows if it will ever become approved for this purpose.

      • ikidd@lemmy.world
        link
        fedilink
        English
        arrow-up
        6
        ·
        1 month ago

        There are one or two countries outside the US that can approve drugs for use.

        • Soulcreator@lemmy.world
          link
          fedilink
          English
          arrow-up
          1
          ·
          1 month ago

          Indeed there are, but just under half of all of medical studies performed world wide are performed in the States, roughly half of the world’s pharmaceutical companies based in the States, and the US has consistently lead the world in medical innovations, with almost 50 percent more innovations than from the EU and Switzerland combined.

          My point is not to sound US centric, but to say there is a lot of capital and willpower in the US pharmaceutical industry, and without that willpower it will be significantly harder to get rapamycin accepted as a viable longevity drug.